From GlobeNewswire:

Corbus Pharmaceuticals Holdings, Inc. announced that their Chief Executive Officer, Yuval Cohen, will provide a corporate update and participate in one-on-one investor meetings at the Oppenheimer 34th Annual Healthcare Life Sciences Conference. The conference will take place virtually on February 13-14, 2024, with Cohen’s presentation scheduled for February 14 at 8:40 a.m. ET. The company is headquartered in Norwood, Massachusetts.

Corbus Pharmaceuticals Holdings, Inc. will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference. The company’s pipeline includes CRB-701, CRB-601, and CRB-913. CRB-701 is a next-generation antibody drug conjugate targeting the expression of Nectin-4 on cancer cells, while CRB-601 is an anti-integrin monoclonal antibody. Corbus is committed to helping people defeat serious illness with innovative scientific approaches. They are headquartered in Norwood, Massachusetts.

This press release contains certain forward-looking statements. Forward-looking statements are based on current expectations, estimates, forecasts, and projections about the industry and markets in which Corbus operates. These forward-looking statements are subject to risks, uncertainties, and other factors, as outlined in the Company’s filings with the Securities and Exchange Commission.

Investors can register for the conference through their Oppenheimer sales representative. For further inquiries, Sean Moran, Chief Financial Officer at Corbus, and Bruce Mackle, Managing Director at LifeSci Advisors, LLC, can be contacted through the information in the press release. You may also contact them via email.



Read more: Corbus Pharmaceuticals to Present at the Oppenheimer 34th